Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant tislelizumab (anti-PD-1 antibody) plus chemotherapy in patients with advanced epithelial ovarian cancer: the exploratory NAIVE trial.

Signal transduction and targeted therapy·2026
Same author

Molecular architecture of language-related cortical areas revealed by integrative proteomic and connectome analyses.

Clinical and translational medicine·2025
Same author

Identification of Active Ingredients in Ginseng Volatile Oil: A Strategy Combining Computer Virtual Screening With Experimental Validation.

Phytochemical analysis : PCA·2024
Same author

Experience With Immediate Internal Fixation Combined With Primary Wound Closure in Gustilo-Anderson Type IIIA Open Ankle Fractures.

The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons·2024
Same author

Effects of a rainwater harvesting system on the soil water, heat and growth of apricot in rain-fed orchards on the Loess Plateau.

Scientific reports·2024
Same author

STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance.

Frontiers in immunology·2024

Related Experiment Video

Updated: Apr 10, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

BRAF inhibitors: the current and the future.

Weijiang Zhang1

  • 1Roche Innovation Center New York, 430 E. 29th Street, New York, NY 10016, United States.

Current Opinion in Pharmacology
|June 15, 2015
PubMed
Summary

BRAF inhibitors (BRAFi) transformed metastatic melanoma care, but skin toxicity and resistance limit effectiveness. Further research is needed for optimal BRAFi cancer therapy.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • BRAF inhibitors (BRAFi) like vemurafenib and dabrafenib have significantly improved outcomes for BRAFV600-mutated metastatic melanoma.
  • Despite their efficacy, BRAFi therapy is associated with cutaneous toxicities and the development of intrinsic and acquired resistance.
  • Understanding these challenges is crucial for advancing melanoma treatment.

Purpose of the Study:

  • To review the impact of BRAF inhibitors on metastatic melanoma treatment.
  • To discuss the mechanisms and challenges related to BRAFi-induced cutaneous toxicity and resistance.
  • To explore emerging therapeutic strategies and future directions in BRAFi therapy.

Main Methods:

  • Literature review of clinical trials and preclinical studies on BRAF inhibitors in melanoma.

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.9K
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.5K

Related Experiment Videos

Last Updated: Apr 10, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K
Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.9K
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.5K
  • Analysis of mechanisms underlying BRAFi efficacy, toxicity, and resistance.
  • Synthesis of current and future therapeutic approaches.

    • Main Results:

    • BRAFi have demonstrated superior response rates and overall survival compared to chemotherapy in BRAFV600-mutated melanoma.
    • Cutaneous toxicities, including rash and photosensitivity, are common side effects.
    • Mechanisms of intrinsic and acquired resistance involve complex signaling pathway alterations.

    Conclusions:

    • BRAFi represent a major advancement in melanoma treatment, but managing toxicity and overcoming resistance are critical.
    • Ongoing research into resistance mechanisms and combination therapies holds promise for improving long-term patient outcomes.
    • Further investigation is required to optimize the clinical application of BRAFi and develop next-generation inhibitors.